4,552 publications from this institution
9-(2-Phosphonylmethoxyethyl)adenine (PMEA), a potent inhibitor of human immunodeficiency virus (HIV), caused a dose-dependent suppression of tumor formation, and mortality associated therewith, in 6-day-old NMRI mice inoculated intracerebrally with Moloney murine sarcoma virus (MSV). Even at a dose as low as 1 mg/kg/day, PMEA effected a significant delay in tumor formation. When evaluated in parallel with PMEA, 3'-azido-2',3'-dideoxythymidine (AZT) conferred a comparable tumor-inhibitory effect at a 5- to 10-fold higher dose than PMEA. Prolonged treatment of MSV-infected mice with PMEA resulted in long-term survivors without apparent signs of tumor development. In view of the propensity of HIV to spread to the central nervous system (CNS), the marked activity shown by PMEA against experimental retrovirus infection of the brain in mice points to its potential in the treatment of AIDS and other retrovirus infections of the CNS.
Abstract ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.
No abstract is provided for this article.
No abstract is provided for this article.
The common scanning strategies in Selective Laser Melting lead to an inhomogeneous melt pool intensity distribution throughout the different layers and scan tracks. This results in various defects such as porosity at the edges, residual stresses, or even excessive warping and delamination. In this research, this issue is resolved by the implementation of an on-line and real-time PID feedback controller. The PID feedback controller will alter the laser power based upon the melt pool intensity resulting in a homogeneous intensity distribution throughout the different scan tracks and layers. 2D intensity maps can be generated from the on-line monitoring system during the production of a benchmark part and will serve as validation for the PID feedback controller.
Adenoviruses (Ads) are common opportunistic pathogens that are rarely associated with severe clinical symptoms in healthy individuals. In contrast, in patients with compromised immunity, Ad infections often result in disseminated and potentially life-threatening disease. Among these are AIDS patients, individuals with hereditary immunodeficiencies and recipients of solid organ or haematopoietic stem cell transplants (HSCT) who receive immunosuppressive therapy. The latter account for the largest number of severe Ad infections. There is currently no formally approved antiviral therapy for the treatment of severe Ad keratoconjunctivitis and life-threatening Ad infections in immunocompromised patients. Here we update current knowledge on Ad biology, the clinical features observed in different patient groups and specific immune responses towards Ad infections. In addition, we review current and future treatment options, including: (i) the antiviral drugs cidofovir, ribavirin and new investigational compounds, as evaluated in the clinic or in relevant animal models, as well as (ii) novel immunotherapeutic strategies.
Abstract In analogy with maribavir [1‐(β‐L‐ribofuranosyl)‐isopropylamino‐5,6‐dichlorobenzimidazole], a nucleoside analogue that acts against human cytomegalovirus (HCMV) by a non‐nucleoside mechanism, here I present three other examples of classes of nucleoside analogues (i.e. bicyclic furo[2,3‐d]pyrimidine as well as HEPT and TSAO derivatives) that act against either HCMV or human immunodeficiency virus (HIV) through a non‐nucleoside mode of action. †In honor and celebration of the 70th birthday of Professor Leroy B. Townsend. Keywords: Neucloside analoguesHCMVHIV Acknowledgment I thank Christiane Callebaut for her proficient editorial assistance. Notes †In honor and celebration of the 70th birthday of Professor Leroy B. Townsend.
No abstract is provided for this article.
No abstract is provided for this article.